Dr. Marnix Bosch to Discuss Factors Related to Patient Survival in Phase I Trial

BETHESDA, MD, September 16, 2015 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Chief Technical Officer, Dr. Marnix Bosch, will present a new DCVax-Direct poster at the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival 2015.  The Conference is being held at the Sheraton New York Times Square Hotel from September 16^th to 19^th, 2015.

This first of its kind conference is a collaboration of four prestigious cancer organizations on both sides of the Atlantic, demonstrating the ever increasing attention towards immunotherapy.  They include the American Association of Cancer Research (AACR), the European Association for Cancer Immunotherapy (CIMT), the Cancer Research Institute (CRI), and the European Academy of Tumor Immunology (EATI).

Dr. Bosch will discuss new and emerging information from the Phase I trial of DCVax-Direct in regard to ongoing patient survival and factors associated with such survival.  The poster is entitled “Cytokine Production by Human Dendritic Cells When Administered Intratumorally Correlates with Clinical Outcome in Subjects with Advanced Cancers.”  This poster presentation will be presented in the 6:45 to 8:45 pm (EDT) Session A on Wednesday, September 16, 2015.

In addition to Dr. Bosch, other authors on the poster presentation include Dr. Vivek Subbiah and colleagues from MD Anderson Hospital and from UT Health in Houston, as well as several representatives from Cognate Bioservices.

The Poster and the accompanying presentation will be posted on the NW Bio website following the presentation at nwbio.com/webcast.  There will be no live webcast of the presentation.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company’s lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.”  The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all types of inoperable solid tumors cancers.  It has completed enrollment in the Phase I portion of the trial.  The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania.  The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer.  In Germany, the Company has received approval of a 5-year Hospital Exemption for the treatment of all gliomas (primary brain cancers) outside the clinical trial.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company’s ongoing ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company’s products will demonstrate safety and efficacy, risks related to the Company’s and Cognate’s abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company’s ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing.  Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings.  Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

CONTACTS

Les Goldman

202-841-7909

lgoldman@nwbio.wpengine.com